 |
English
|
正體中文
|
简体中文
|
Post-Print筆數 : 27 |
Items with full text/Total items : 113160/144130 (79%)
Visitors : 50736435
Online Users : 353
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/75175
|
| Title: | Sarcosine therapy for obsessive compulsive disorder: A prospective, open-label study |
| Authors: | Wu, P.-L.;Tang, Hwa-Sheng;Lane, H.-Y.;Tsai, C.-A.;Tsai, G.E.
湯華盛 |
| Contributors: | 心理系 |
| Keywords: | alprazolam;amitriptyline;citalopram;clomipramine;clonazepam;escitalopram;fluoxetine;fluvoxamine;haloperidol;imipramine;olanzapine;paroxetine;risperidone;sarcosine;serotonin uptake inhibitor;sertraline;valproic acid;venlafaxine;zotepine;adult;article;clinical article;drug response;drug tolerability;drug withdrawal;dysthymia;female;headache;human;major depression;male;monotherapy;obsessive compulsive disorder;open study;priority journal;prospective study;Adult;Drug Therapy, Combination;Female;Glycine Plasma Membrane Transport Proteins;Humans;Male;Middle Aged;Obsessive-Compulsive Disorder;Psychiatric Status Rating Scales;Psychotropic Drugs;Sarcosine |
| Date: | 2011-06 |
| Issue Date: | 2015-05-18 17:35:19 (UTC+8) |
| Abstract: | Background: Several lines of evidence implicate glutamatergic neurotransmission in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine is an endogenous antagonist of glycine transporter-1. By blocking glycine uptake, sarcosine may increase the availability of synaptic glycine and enhance N-methyl-d-aspartate (NMDA) subtype glutamatergic neurotransmission. In this 10-week open-label trial, we examined the potential benefit of sarcosine treatment in OCD patients. Method: Twenty-six outpatients with OCD and baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) scores higher than 16 were enrolled. Drug-naive subjects (group 1, n = 8) and those who had discontinued serotonin reuptake inhibitors for at least 8 weeks at study entry (group 2, n = 6) received sarcosine monotherapy. The other subjects (group 3, n = 12) received sarcosine as adjunctive treatment. A flexible dosage schedule of sarcosine 500 to 2000 mg/d was applied. The primary outcome measures were Y-BOCS and Hamilton Anxiety Inventory, rated at weeks 0, 2, 4, 6, 8, and 10. Results were analyzed by repeated-measures analysis of variance. Results: Data of 25 subjects were eligible for analysis. The mean ± SD Y-BOCS scores decreased from 27.6 ± 5.8 to 22.7 ± 8.7, indicating a mean decrease of 19.8% ± 21.7% (P = 0.0035). Eight (32%) subjects were regarded as responders with greater than 35% reduction of Y-BOCS scores. Five of the responders achieved the good response early by week 4. Although not statistically significant, drug-naive (group 1) subjects had more profound and sustained improvement and more responders than the subjects who had received treatment before (groups 2 and 3). Sarcosine was tolerated well; only one subject withdrew owing to transient headache. Conclusion: Sarcosine treatment can achieve a fast therapeutic effect in some OCD patients, particularly those who are treatment naive. The study supports the glycine transporter-1 as a novel target for developing new OCD treatment. Large-series placebo-controlled, double-blind studies are recommended. © 2011 Lippincott Williams & Wilkins. |
| Relation: | Journal of Clinical Psychopharmacology, 31(3), 369-374 |
| Data Type: | article |
| DOI 連結: | http://dx.doi.org/10.1097/JCP.0b013e3182189878 |
| DOI: | 10.1097/JCP.0b013e3182189878 |
| Appears in Collections: | [心理學系] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 20110527114746.pdf | | 187Kb | Adobe PDF2 | 812 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
著作權政策宣告 Copyright Announcement1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.
2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(
nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(
nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
